Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 13
    records per page




    Comparative analysis of immune-associated genes in COVID-19, cardiomyopathy HP cardiomyopathy MESHD and venous thromboembolism MESHD thromboembolism HP

    Authors: Grant E Castaneda; Abby C Lee; Wei Tse Li; Chengyu Chen; Jaideep Chakladar; Eric Chang; Weg Ongkeko; Xiaojian Liu; Wei Gao; Renli Zhang; Qiru Su; Andrew Azman; Justin Lessler; Xuan Zou; Wenfeng Gong; Brenda Clemente; Jerel Vega; Scott Roberts; Jose A. Gonzalez; Marciano Sablad; Rodrigo Yelin; Wendy Taylor; Kiyoshi Tachikawa; Suezanne Parker; Priya Karmali; Jared Davis; Sean M Sullivan; Steve G. Hughes; Pad Chivukula; Eng Eong Ooi

    doi:10.1101/2020.08.28.20184234 Date: 2020-09-02 Source: medRxiv

    As of 28 August 2020, there have been 5.88 million Coronavirus Disease MESHD 2019 (COVID-19) cases and 181,000 COVID-19 related deaths in the United States alone. Given the lack of an effective pharmaceutical treatment for COVID-19, the high contagiousness of the disease and its varied clinical outcomes, identifying patients at risk of progressing to severe disease is crucial for the allocation of valuable healthcare resources during this pandemic. Current research has shown that there is a higher prevalence SERO of cardiovascular comorbidities amongst patients with severe COVID-19 or COVID-19-related deaths, but the link between cardiovascular disease MESHD and poorer prognosis is poorly understood. We believe that pre-existing immune dysregulation HP that accompanies cardiovascular disease MESHD predisposes patients to a harmful inflammatory immune response, leading to their higher risk of severe disease. Thus, in this project, we aim to characterize immune dysregulation HP dysregulation MESHD in patients with cardiomyopathy HP cardiomyopathy MESHD, venous thromboembolism MESHD thromboembolism HP and COVID-19 patients by looking at immune-associated gene dysregulation, immune HP infiltration and dysregulated immunological pathways and gene signatures.

    Incidence of thromboembolism HP thromboembolism MESHD in patients with COVID-19: a systematic review and meta-analysis

    Authors: Kochawan Boonyawat; Pichika Chantrathammachart; Pawin Numthavej; Nithita Nanthatanti; Sithakom Phusanti; Angsana Phuphuakrat; Pimjai Niparuck; Pantep Angchaisuksiri

    doi:10.21203/rs.3.rs-63530/v1 Date: 2020-08-21 Source: ResearchSquare

    Background Since the beginning of the coronavirus disease MESHD 2019 (COVID-19) pandemic, the incidence of thromboembolism HP thromboembolism MESHD has been increasingly reported. The aim of this systematic review was to explore the incidence of venous and arterial thromboembolism MESHD thromboembolism HP among COVID-19 patients requiring hospitalization.Methods Medline, Embase, Scopus, and grey literature were searched until May 2020. Observational studies reported on the incidence of venous thromboembolism MESHD thromboembolism HP ( VTE MESHD), including pulmonary embolism HP pulmonary embolism MESHD ( PE MESHD) and deep vein thrombosis MESHD ( DVT MESHD) or arterial thromboembolism MESHD thromboembolism HP ( ATE MESHD) were included. The pool incidences and their 95% confidence intervals (CI) were calculated using the random-effects model.Results A total of 26 studies were included. In the intensive care unit (ICU) setting, the pooled incidence of VTE MESHD was 27% (95% CI, 20–35%). Subgroups based on compression ultrasound (CUS) screening revealed a higher incidence of DVT MESHD in the CUS screening group than in the no CUS screening group (27% [95% CI, 20–35%] vs. 3% [95% CI, 1–5%]). The pooled incidence of ATE MESHD in ICU was 3% (95% CI, 2–4%). In the non-ICU setting, the pooled incidence of VTE MESHD was 8% (95% CI, 4–12%,).Conclusions The incidence of VTE MESHD in COVID-19 patients was higher in the ICU setting than in the non-ICU setting, and also significantly higher in studies that incorporated the CUS screening protocol. The incidence of ATE MESHD in the ICU setting was low. VTE MESHD prophylactic measures should be given to all hospitalized patients diagnosed with COVID-19, especially in the ICU setting.

    High Incidence of Venous Thromboembolism MESHD Thromboembolism HP in Patients with Coronavirus Disease MESHD 2019: A Call for Improved Awareness and Prevention

    Authors: Yun-xia Zhang; Meng Zhang; Yimin Wang; Wei Qin; Zhu Zhang; Chenghong Li; Zhenguo Zhai

    doi:10.21203/rs.3.rs-60522/v1 Date: 2020-08-16 Source: ResearchSquare

    Background: An increased risk of venous thromboembolism MESHD thromboembolism HP ( VTE MESHD) in patients with coronavirus disease MESHD 2019 (COVID-19) has been reported. We performed a meta-analysis to evaluate the prevalence SERO of VTE MESHD in COVID-19 patients.Methods: The PubMed and Embase databases were searched for studies reporting VTE MESHD in COVID-19 patients up to June 27, 2020. The selected studies were predefined into the “suspected screening group” and the “routine screening group.” The VTE MESHD prevalence SERO was calculated using random-effect models.Results: We selected 20 studies including a total of 2763 COVID-19 patients. In 2203 COVID-19 patients from the suspected screening group, the pool VTE MESHD incidence was 15.2% (95% confidence interval [CI]: 10.5–21.6%). In 560 COVID-19 patients from the routine screening group, the VTE MESHD prevalence SERO was 40.8% (95% CI: 20.6–64.7%). Furthermore, the VTE MESHD incidence of critically ill COVID-19 patients from the two groups was 19.6% and 61.4%, respectively, which indicates that critically ill COVID-19 patients were more susceptible to VTE MESHD.Conclusions: A high incidence of VTE MESHD was observed in COVID-19 patients, especially in severe cases. The incidence of VTE MESHD in COVID-19 patients from the routine screening group was higher than that in patients from the suspected screening group. This indicates that a lower threshold of suspicion to perform VTE MESHD imaging tests may be reasonable and there is an urgent need to adapt a regular screening strategy for VTE MESHD.

    COVID-19 induces a hyperactive MESHD phenotype in circulating platelets

    Authors: Shane P Comer; Sarah Cullivan; Paulina B Szklanna; Luisa Weiss; Steven Cullen; Sarah Kelliher; Albert Smolenski; Niamh Moran; Claire Murphy; Haidar Altaie; John Curran; Katherine O'Reilly; Aoife G Cotter; Brian Marsh; Sean Gaine; Patrick Mallon; Brian McCullagh; Fionnuala Ní Áinle; Barry Kevane; Patricia B Maguire

    doi:10.1101/2020.07.24.20156240 Date: 2020-07-26 Source: medRxiv

    Background Coronavirus disease MESHD 2019 (COVID-19), caused by novel coronavirus SARS-CoV-2 MESHD, has to date affected over 13.3 million globally. Although high rates of venous thromboembolism MESHD thromboembolism HP and evidence of COVID-19-induced endothelial dysfunction have been reported, the precise aetiology of the increased thrombotic MESHD risk associated with COVID-19 infection MESHD remains to be fully elucidated. Objectives Here, we assessed clinical platelet parameters and circulating platelet activity in patients with severe and non-severe COVID-19. Methods An assessment of clinical blood SERO parameters in patients with severe COVID-19 disease MESHD (requiring intensive care), patients with non-severe disease (not requiring intensive care), general medical in-patients without COVID-19 and healthy donors was undertaken. Platelet function and activity were also assessed by secretion and specific marker analysis. Results We show that routine clinical blood SERO parameters including increased MPV and decreased platelet:neutrophil ratio are associated with disease severity in COVID-19 upon hospitalisation and intensive care unit admission. Strikingly, agonist-induced ADP release was dramatically higher in COVID-19 patients compared with non-COVID-19 hospitalized patients and circulating levels of PF4, sP-selectin and TPO were also significantly elevated in COVID-19. Conclusion Distinct differences exist in routine full blood SERO count and other clinical laboratory parameters between patients with severe and non-severe COVID-19. Moreover, we have determined that COVID-19 patients possess hyperactive circulating platelets. These data suggest that abnormal platelet reactivity may contribute to hypercoagulability HP hypercoagulability MESHD in COVID-19. Further investigation of platelet function in COVID-19 may provide additional insights into the aetiology of thrombotic risk in this disease and may contribute to the optimisation of thrombosis MESHD prevention and treatment strategies.

    Tocilizumab and Thromboembolism HP Thromboembolism MESHD in COVID-19: A Retrospective Hospital-based Cohort Analysis

    Authors: Kok Hoe Chan; Bhavik Patel; Bishnu Podel; Maria E Szabela; Hamid S Shaaban; Gunwant Guron; Jihad Slim

    doi:10.21203/rs.3.rs-39943/v1 Date: 2020-07-02 Source: ResearchSquare

    Background:Tocilizumab, an IL-6 receptor antagonist has been used in patients with Coronavirus Disease MESHD 2019 (COVID-19) as an anti-cytokine agent. IL-6 also plays a complex role in hemostasis and thrombosis MESHD. We observed a transient elevation of D-dimer in our patients who received Tocilizumab, which triggered the current study.Methods:A retrospective hospital-based cohort analysis of patients with confirmed COVID-19 who received Tocilizumab during the study period of 03/15/2020 to 05/20/2020. We retrieved demographic, clinical and laboratory data, we excluded patients who were receiving therapeutic anticoagulation therapy prior to Tocilizumab administration.  Descriptive analysis was performed, the cause of death MESHD and trends of D-dimer and inflammatory markers were studied. Results: Out of the 436 confirmed COVID 19 patients admitted during the study period, 24 met the inclusion criteria. Their median age TRANS was 47.5 years old. They were 18 males TRANS and 6 females TRANS; 15 patients survived, and 9 expired. Of the group that survived, 12 received therapeutic anticoagulation. Of the 7 patients who did not receive therapeutic anticoagulation, 4 expired, 1 from sepsis HP sepsis MESHD and 3 probably from thromboembolic complications MESHD, compared to 5 deaths in the 17 patients who received therapeutic anticoagulation with 4 dying from sepsis HP sepsis MESHD, and one possibly from thromboembolic complications MESHD.Conclusions:The interplay between IL-6, IL-6 receptor antagonist and venous thromboembolism MESHD thromboembolism HP are complex. We observed a transient elevation of D-dimer in COVID-19 patients who received Tocilizumab, and a trend toward increased death secondary to thromboembolism HP thromboembolism MESHD. This observation is novel and highlights the potential thrombophilic side effects of Tocilizumab.

    Deep Venous Thrombosis HP Deep Venous Thrombosis MESHD in COVID-19 Patients: A Cohort Analysis

    Authors: Yi Guo; Yun You; Ke Hu; Fei Cai; Yiqing Li; Mingxing Xie; Lu Yang; Dawei Ye; Ken Ling; Sanjay Misra; Weici Wang; chuanqi cai

    doi:10.21203/rs.3.rs-39414/v1 Date: 2020-07-01 Source: ResearchSquare

    BackgroundDeep venous thrombosis HP venous thrombosis MESHD (DVT) is a severe complication of the coronavirus disease MESHD 2019 (COVID-19). It may interfere with COVID-19 treatment and delay the recovery, but there is less data about the anticoagulant therapy and sex difference of VTE MESHD in patients with COVID-19. The purpose of this study is to study the prevalence SERO, risk factors, anticoagulant therapy and sex difference of deep venous thrombosis HP deep venous thrombosis MESHD ( DVT MESHD) in patients with COVID-19.MethodsThe enrolled 121 patients were confirmed positive for COVID-19. All suspected patients with a high Caprini index (≥4) or PADUA index (≥4) received color Doppler Ultrasound (US) to screen DVT MESHD in both lower extremities. Clinical characteristics of DVT MESHD-COVID-19 patients were analyzed. Multivariate logistic regression was performed to identify risk factors related to DVT MESHD in COVID-19 patients. The distribution of DVT MESHD locations, anticoagulation therapy with sex difference, and the outcomes were also analyzed.ResultsDVT was found in 48% asymptomatic TRANS COVID-19 patients with increased PAUDA index or Caprini index by US scanning. Multivariate logistic regression determined that age TRANS, CRP and baseline D-dimer were risk factors among COVDI-19 patients. Although the most common DVT MESHD location was infrapopliteal (Class I and Class II), higher mortality in DVT MESHD-COVID-19 patients was confirmed. DVT MESHD-COVID-19 patients presented significant increases in the CRP, neutrophil count and D-dimer throughout the whole inpatient period compared to non- DVT MESHD-COVID-19 patients. Although anticoagulation therapy accelerated the recovery of lymphocytopenia condition MESHD in DVT MESHD patients, men DVT MESHD-COVID-19 patients showed higher CRP and neutrophil count vs. lymphocyte count (N/L) ratio but lower lymphocyte count compared to women DVT MESHD-COVID-19 patients. ConclusionsDVT is common in COVID-19 patients with high risk factors, especially for older age TRANS, higher CRP and baseline D-dimer populations. It is important to consider sex differences in the anticoagulant therapy among DVT MESHD-COVID-19 patients.

    The validation of the original and modified Caprini score in COVID-19 patients

    Authors: Sergey Tsaplin; Ilya Schastlivtsev; Kirill Lobastov; Sergey Zhuravlev; Victor Barinov; Joseph Caprini

    doi:10.1101/2020.06.22.20137075 Date: 2020-06-23 Source: medRxiv

    Objective. The study aimed to validate the original Caprini score and its modifications considering coronavirus disease MESHD (COVID-19) as a severe prothrombotic condition MESHD in patients admitted to the hospital with confirmed infection TRANS infection MESHD. Methods. The relevant data were extracted from the electronic medical records with the implemented Caprini score and were evaluated retrospectively. The score was calculated twice: by the physician at the admission and by the investigator at discharge or after death. The second calculation at discharge, considered additional risk factors that occurred during inpatient treatment. Besides the original Caprini score (a version of 2005), the modified version added the elevation of D-dimer and specific scores for COVID-19 as follows: 2 points for asymptomatic TRANS, 3 points for symptomatic and 5 points for symptomatic infection MESHD with positive D-dimer, were evaluated in a retrospective manner. The primary endpoint was symptomatic venous thromboembolism MESHD thromboembolism HP ( VTE MESHD) confirmed by appropriate imaging testing or dissection. The secondary endpoint included the unfavorable outcome as a combination of symptomatic VTE MESHD, admission to the intensive care unit, the requirement for invasive mechanical ventilation, and death MESHD. The association of eight different versions of the Caprini score with outcomes was evaluated. Results. Totally 168 patients (83 males TRANS and 85 females TRANS at the age TRANS of 58.3{+/-}12.7 years old) were admitted to the hospital between April 30 and May 29, 2020, and were discharged or died up to the time of data analysis. The original Caprini score varied between 2-12 (5.4{+/-}1.8) at the admission and between 2-15 (5.9{+/-}2.5) at discharge or death MESHD. The presence of the virus increased these scores and resulted in an increased score with the maximal value for those including COVID-19 points (10.0{+/-}3.0). Patients received prophylactic (2.4%), intermediate (76.8%), or therapeutic (20.8%) doses of enoxaparin. Despite this, the symptomatic VTE MESHD was detected in 11 (6.5%) and unfavorable outcomes in 31 (18.5%) patients. The Caprini score of all eight versions demonstrated a significant association with VTE MESHD with the highest predictability for the original scale when assessed at discharge. Supplementation of the original score by elevated D-dimer improved predictability only at the admission. Four versions of the Caprini score calculated at the admission had a significant correlation with the unfavorable outcome with the minor advantages of specific COVID-19 points. Conclusion. The study identified a significant correlation between the Caprini score and the risk of VTE MESHD or unfavorable outcomes in COVID-19 patients. All models, including specific COVID-19 scores, showed high predictability with minor differences.

    Clinical Characteristics and Outcomes of Venous Thromboembolism MESHD Thromboembolism HP in Patients Hospitalized for COVID-19: Systematic Review and Meta-Analysis

    Authors: Joshua Henrina; Iwan Cahyo Santosa Putra; Irvan Cahyadi; Hoo Felicia Hadi Gunawan; Alius Cahyadi; Leonardo Paskah Suciadi

    doi:10.1101/2020.06.14.20130922 Date: 2020-06-16 Source: medRxiv

    Objective: To investigate the clinical characteristics and outcomes of Coronavirus Disease MESHD of 2019 (COVID-19) patients complicated with venous thromboembolism MESHD thromboembolism HP ( VTE MESHD) Method: We performed a comprehensive literature search of several databases to find studies that assessed VTE MESHD in hospitalized COVID-19 patients with a primary outcome of all-cause mortality and secondary outcomes of intensive care unit (ICU) admission and mechanical ventilation. We also evaluated the clinical characteristics of VTE MESHD sufferers. Objective: To investigate the clinical characteristics and outcomes of Coronavirus Disease MESHD of 2019 (COVID-19) patients complicated with venous thromboembolism MESHD thromboembolism HP ( VTE MESHD) Method: We performed a comprehensive literature search of several databases to find studies that assessed VTE MESHD in hospitalized COVID-19 patients with a primary outcome of all-cause mortality and secondary outcomes of intensive care unit (ICU) admission and mechanical ventilation. We also evaluated the clinical characteristics of VTE MESHD sufferers. Results: Eight studies have been included with a total of 1237 pooled subjects. Venous thromboembolism MESHD thromboembolism HP was associated with higher mortality (RR 2.48 (1.35, 4.55), p=0.003; I2 5%, p=0.35) after we performed sensitivity SERO analysis, ICU admission (RR 2.32 (1.53, 3.52), p<0.0001; I2 80%, p <0.0001), and mechanical ventilation need (RR 2.73 (1.56, 4.78), p=0.0004; I2 77%, p=0.001). Furthermore, it was also associated to male TRANS gender TRANS (RR 1.21 (1.08, 1.35), p=0.0007; I2 12%, p=0.34), higher white blood SERO cells count (MD 1.24 (0.08, 2.41), 0.04; I2 0%; 0.26), D-dimer (MD 4.49 (2.74, 6.25), p<0.00001; I2 67%, p=0.009) and LDH levels (MD 70.93 (19.33, 122.54), p<0.007; I2 21%, p=0.28). In addition, after sensitivity SERO analysis was conducted, VTE MESHD also associated with older age TRANS ( MD MESHD 2.79 (0.06, 5.53), p=0.05; I2 25%, p=0.24) and higher CRP levels (MD 2.57 (0.88, 4.26); p=0.003; I2 0%, p=0.96). Conclusion: Venous thromboembolism MESHD thromboembolism HP in COVID-19 patients was associated with increased mortality, ICU admission, and mechanical ventilation requirement. Male TRANS gender TRANS, older age TRANS, higher levels of biomarkers, including WBC count, D-Dimer, and LDH were also being considerably risks for developing VTE MESHD in COVID-19 patients during hospitalization. Conclusion: Venous thromboembolism MESHD thromboembolism HP in COVID-19 patients was associated with increased mortality, ICU admission, and mechanical ventilation requirement. Male TRANS gender TRANS, older age TRANS, higher levels of biomarkers, including WBC count, D-Dimer, and LDH were also being considerably risks for developing VTE MESHD in COVID-19 patients during hospitalization.

    Risk factors for clinical progression in patients with COVID-19: a retrospective study of electronic health record data in the United Kingdom

    Authors: Robert A Fletcher; Thomas Matcham; Marta Tibúrcio; Arseni Anisimovich; Stojan Jovanović; Luca Albergante; Nadezda Lipunova; Anne Hancock; Lucy Mackillop; Lionel Tarassenko; Alex McCarthy; Marcela P Vizcaychipi; Rabia Tahir Khan

    doi:10.1101/2020.05.11.20093096 Date: 2020-05-15 Source: medRxiv

    Background: The novel coronavirus disease MESHD 2019 (COVID-19) outbreak presents a significant threat to global health. A better understanding of patient clinical profiles is essential to drive efficient and timely health service strategies. In this study, we aimed to identify risk factors for a higher susceptibility to symptomatic presentation with COVID-19 and a transition to severe disease. Methods: We analysed data on 2756 patients admitted to Chelsea & Westminster Hospital NHS Foundation Trust between 1st January and 23rd April 2020. We compared differences in characteristics between patients designated positive for COVID-19 and patients designated negative on hospitalisation and derived a multivariable logistic regression model to identify risk factors for predicting risk of symptomatic COVID-19. For patients with COVID-19, we used univariable and multivariable logistic regression to identify risk factors associated with progression to severe disease defined by: 1) admission to the hospital AICU, 2) the need for mechanical ventilation, 3) in-hospital mortality, and 4) at least one measurement of elevated D-dimer (equal or superior to 1,000 ug/L) indicative of increased risk of venous thromboembolism MESHD thromboembolism HP. Results: The patient population consisted of 1148 COVID-19 positive and 1608 COVID-19 negative patients. Age TRANS, sex, self-reported ethnicity, C-reactive protein, white blood SERO cell count, respiratory rate, body temperature, and systolic blood SERO pressure formed the most parsimonious model for predicting risk of symptomatic COVID-19 at hospital admission. Among 1148 patients with COVID-19, 116 (10.1%) were admitted to the AICU, 71 (6.2%) required mechanical ventilation, 368 (32.1%) had at least one record of D-dimer levels [≥]1,000 g/L, and 118 patients died. In the multivariable logistic regression, age TRANS (OR = 0.953 per 1 year, 95% CI: 0.937-0.968) C-reactive protein (OR = 1.004 per 1 mg/L, 95% CI: 1.002-1.007), and white blood SERO cell counts (OR = 1.059 per 109/L, 95% CI: 1.010-1.111) were found to be associated with admission to the AICU. Age TRANS (OR = 0.973 per 1 year, 95% CI: 0.955-0.990), C-reactive protein (OR = 1.003 per 1 mg/L, 95% CI: 1.000-1.006) and sodium (OR = 0.915 per 1 mmol/L, 0.868-0.962) were associated with mechanical ventilation. Age TRANS (OR = 1.023 per 1 year, 95% CI: 1.004-1.043), CRP (OR = 1.004 per 1 mg/L, 95% CI: 1.002-1.006), and body temperature (OR = 0.723 per 1oC, 95% CI: 0.541-0.958) were associated with elevated D-dimer. For mortality, we observed associations with age TRANS (OR = 1.060 per 1 year, 95% CI: 1.040-1.082), female TRANS sex (OR = 0.442, 95% CI: 0.442, 95% CI: 0.245-0.777), Asian ethnic background (OR = 2.237 vs White ethnic background, 95% CI: 1.111-4.510), C-reactive protein (OR = 1.004 per 1 mg/L, 95% CI: 1.001-1.006), sodium (OR = 1.038 per 1 mmol/L, 95% CI: 1.001-1.006), and respiratory rate (OR = 1.054 per 1 breath MESHD/min, 95% CI: 1.024-1.087). Conclusion: Our analysis suggests there are several demographic, clinical and laboratory findings associated with a symptomatic presentation of COVID-19. Moreover, significant associations between patient deterioration were found with age TRANS, sex and specific blood SERO markers, chiefly C-reactive protein, and could help early identification of patients at risk of poorer prognosis. Further work is required to clarify the extent to which our observations are relevant beyond current settings.

    Aortic Thrombus MESHD in patients with Severe Covid-19. Review of three cases

    Authors: Maria Carranza; Danilo Salazar; Jesús Troya; Roberto Alcazar; Cristina Peña; Nuria Muñoz

    doi:10.21203/rs.3.rs-28657/v1 Date: 2020-05-12 Source: ResearchSquare

    Coronavirus disease MESHD 2019 (COVID-19) is suspected to predispose to both venous and arterial thromboembolism MESHD thromboembolism HP, in the context of an exaggerated immune response to the virus, especially in severe patients. Even though aortic thrombi MESHD are a rare entity, the new COVID-19 establishes the need to include them in the diagnosis, especially in patients with severe disease and no clinical improvement. Herein, we describe a series of three cases of aortic thrombi MESHD diagnosed by computerized tomography (CT) angiography in patients with confirmed SARS CoV-2 infection MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.